Carotenoids Composition of Green Algae Caulerpa racemosa and Their Antidiabetic, Anti-Obesity, Antioxidant, and Anti-Inflammatory Properties

Molecules, Journal Year: 2023, Volume and Issue: 28(7), P. 3267 - 3267

Published: April 6, 2023

Green alga Caulerpa racemosa is an underexploited species of macroalgae, even though it characterized by a green color that indicates abundance bioactive pigments, such as chlorophyll and possibly xanthophyll. Unlike chlorophyll, which has been well explored, the composition carotenoids C. its biological activities have not reported. Therefore, this study aims to look at carotenoid profile racemose determine their activities, include antidiabetic, anti-obesity, anti-oxidative, anti-inflammatory, cytotoxicity in vitro. The detected were all xanthophylls, included fucoxanthin, lutein, astaxanthin, canthaxanthin, zeaxanthin, β-carotene, β-cryptoxanthin based on orbitrap-mass spectrometry (MS) rapid ultra-high performance liquid chromatography (UHPLC) diode array detector. Of seven observed, should be highlighted β-carotene canthaxanthin two most dominant present racemosa. Interestingly, extract good activity inhibiting α-glucosidase, α-amylase, DPPH ABTS, TNF-α mTOR, upregulating AMPK, makes drug candidate or functional antidiabetic food, very promising anti-obesity anti-inflammatory. More interestingly, value shows level safety normal cells, potential for further development nutraceuticals pharmaceuticals.

Language: Английский

---

The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes

Cell Host & Microbe, Journal Year: 2024, Volume and Issue: 32(8), P. 1280 - 1300

Published: Aug. 1, 2024

Language: Английский

---

Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: March 21, 2024

Diabetic retinopathy, nephropathy, and neuropathy are significant microvascular complications of diabetes mellitus, contributing to substantial morbidity mortality worldwide. This comprehensive review examines the clinical relationship between these complications, focusing on shared pathophysiological mechanisms, bidirectional relationships, implications for patient management. The highlights importance understanding interconnected nature diabetic adopting a holistic approach care. Insights gleaned from this underscore necessity early detection, timely intervention, integrated care models involving collaboration among healthcare professionals. Furthermore, emphasizes need continued research elucidate underlying identify novel therapeutic targets, assess efficacy strategies in improving outcomes. By fostering interdisciplinary knowledge exchange, future endeavors hold potential advance our management ultimately enhancing quality life.

Language: Английский

---

The Kidney in Obesity: Current Evidence, Perspectives and Controversies

Current Obesity Reports, Journal Year: 2024, Volume and Issue: 13(4), P. 680 - 702

Published: Aug. 14, 2024

Language: Английский

---

Predicting the onset of chronic kidney disease (CKD) for diabetic patients with aggregated longitudinal EMR data

PLOS Digital Health, Journal Year: 2025, Volume and Issue: 4(1), P. e0000700 - e0000700

Published: Jan. 22, 2025

Chronic kidney disease (CKD) affects over 13% of the population, totaling more than 800 million individuals worldwide. Timely identification and intervention are crucial to delay CKD progression improve patient outcomes. This research focuses on developing a predictive model classify diabetic patients showing signs function impairment based their development risk. Our utilizes electronic medical record (EMR) data, specifically by incorporating demographics, laboratory results, chronic conditions, risk factors, medication codes predict onset in six months advance, achieving an average Area Under Curve (AUC) 0.88. We leverage aggregated EMR data effectively capture relevant information within observation year instead using temporal data. Furthermore, we identify most significant features for predicting onset, including mean, minimum, first quartile estimated glomerular filtration rate (eGFR) during year, along with variables such as diagnosis age duration hypertension, osteoarthritis, diabetes, well levels hemoglobin fasting blood glucose (FBG). also explored refined utilizing only these features, which yields slightly lower AUC 0.86. These typically available primary empowering physicians real-time assessment. The proposed model’s ability higher-risk is essential timely intervention, personalized care, stratification, education, potential cost savings. contributes valuable insights healthcare practitioners seeking efficient tools early detection populations.

Language: Английский

---

Symptom Burden before and after Dialysis Initiation in Older Patients

Clinical Journal of the American Society of Nephrology, Journal Year: 2022, Volume and Issue: 17(12), P. 1719 - 1729

Published: Nov. 10, 2022

For older patients with kidney failure, lowering symptom burden may be more important than prolonging life. Dialysis initiation affect individual failure-related symptoms differently, but the change in before and after start of dialysis has not been studied. Therefore, we investigated course total number starting patients.The European Quality (EQUAL) study is an ongoing, prospective, multicenter ≥65 years incident eGFR ≤20 ml/min per 1.73 m2. Using index (DSI), 30 were assessed every 3-6 months between 2012 2021. Scores for range from zero to and, burden, 150, higher scores indicating severity. mixed effects models, studied during year preceding initiation.We included 456 on who filled out at least one DSI or dialysis. At initiation, mean (SD) participant age was 76 (6) years, 75% men, 8 (3) m2, 44% had diabetes, 46% cardiovascular disease. In increased +3.6 (95% confidence interval [95% CI], +2.5 +4.6) +13.3 CI, +9.5 +17.0). after, changed -0.9 -3.4 +1.5) decreased -5.9 -14.9 -3.0). "fatigue," "decreased interest sex," "difficulty becoming sexually aroused" highest prevalence 81%, 69%, 68%, respectively, a 2.7, 2.4, 2.3, respectively. "Fatigue" somewhat improved whereas sexual further increased.Symptom worsened considerably stabilized initiation. "Fatigue," considered most burdensome, which only "fatigue"

Language: Английский

---

Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway

International Journal of Molecular Medicine, Journal Year: 2024, Volume and Issue: 53(3)

Published: Jan. 17, 2024

The senolytics dasatinib and quercetin (DQ) alleviate age‑related disorders. However, limited information is available regarding the effects of DQ on diabetic kidney disease (DKD). present study aimed to explore DKD its potential molecular mechanism(s). Dasatinib (5 mg/kg) (50 were administered db/db mice by gavage for 20 weeks. Body weight, urine albumin‑creatinine ratio (ACR), serum creatinine (Scr), blood urea nitrogen (BUN) recorded at indicated time periods. Periodic acid‑Schiff Masson's staining performed assess histopathological changes tissues. Immunohistochemical analysis, immunofluorescence western blotting evaluate expression levels extracellular matrix (ECM) proteins, autophagic podocyte differentiation‑related proteins. In addition, mouse podocytes with high‑glucose, 3‑methyladenine (3‑MA), proteins measured. Moreover, following overexpression Notch intracellular domain (NICD), NICD, further assessed. significantly reduced body glucose, ACR, Scr BUN improved induced in mice. caused a significant downregulation ECM autophagy an upregulation Administration 3‑MA differentiation, NICD could reverse differentiation in vitro. suggests that protects against activation dedifferentiation via pathway.

Language: Английский

---

Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(S5), P. 25 - 34

Published: July 23, 2024

Chronic kidney disease (CKD) associated with type 2 diabetes (T2DM) is a global challenge; progression to end-stage (ESKD) and increased risk of cardiovascular (CVD) advancing nephropathy are significant source morbidity, mortality, healthcare expenditure. Until recently, renin-angiotensin system (RAS) blockade was the mainstay pharmacotherapy in diabetic (DKD), representing therapeutic paradigm shift towards interventions that delay independently antihypertensive effects. However, residual DKD persisted patients established on RAS blockade, highlighting need for additional treatment options. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally licensed as glucose-lowering agents people T2DM, serendipitously demonstrated beneficial renal outcomes clinical trials designed primarily evaluate their safety. The Canagliflozin Renal Events Diabetes Established Nephropathy Clinical Evaluation (CREDENCE) trial first study effect SGLT2 inhibition primary composite endpoint ESKD, doubling serum creatinine, or death 4401 T2DM CKD blockade. stopped early due efficacy, demonstrating 30% relative reduction canagliflozin group (hazard ratio 0.70, 95% confidence interval 0.59-0.82; p = 0.00001). Through discussion analysis from CREDENCE, selected post hoc analyses, we review benefits highlighted by this landmark study, its role shaping guidelines, re-establishing interest reduce DKD, alongside interrelation morbidity heart failure. We also provide brief narrative summary key outcome since which indicate emerging avenues beyond inhibition.

Language: Английский

---

The Role of GLP-1, GIP, MCP-1 and IGFBP-7 Biomarkers in the Development of Metabolic Disorders: A Review and Predictive Analysis in the Context of Diabetes and Obesity

Biomedicines, Journal Year: 2024, Volume and Issue: 12(1), P. 159 - 159

Published: Jan. 11, 2024

Metabolic illnesses, including obesity and type 2 diabetes, have become worldwide epidemics that an effect on public health. Clinical investigations further exploration of these mechanisms could lead to innovative, effective, personalized treatment strategies for individuals. It is important screen biomarkers in previous studies discover what missing. Glucagon-like peptide-1's role insulin secretion glucose control highlights its diagnostic therapeutic potential. Glucose-dependent insulinotropic peptide's influence postprandial satiety weight management signifies importance understanding metabolic processes. Monocyte chemoattractant protein-1's involvement inflammation resistance underlines value as a marker. Insulin-like growth factor-binding protein-7's association with sensitivity kidney function presents it potential target diseases' management. In validating biomarkers, will be easier reflect pathophysiological processes, clinicians able better assess disease severity, monitor progression, tailor strategies. The purpose the study was elucidate significance identifying novel diabetes mellitus obesity, which can revolutionize early detection, risk assessment, Standard literature searches PubMed (MEDLINE), EMBASE, Cochrane Library were conducted year 2023 identify both original RCTs recent systematic reviews explored T2D obesity. This search produced 1964 results, then reduced randomized controlled trial reviews, producing 145 results 44 respectively. Researchers discovered associations between glucagon-like peptide-1, glucose-dependent peptide, monocyte protein-1, insulin-like protein-7. Understanding those pathogenesis offers hope improving diagnostics, treatment, prevention

Language: Английский

---

A digital twin model incorporating generalized metabolic fluxes to identify and predict chronic kidney disease in type 2 diabetes mellitus

npj Digital Medicine, Journal Year: 2024, Volume and Issue: 7(1)

Published: May 24, 2024

Abstract We have developed a digital twin-based CKD identification and prediction model that leverages generalized metabolic fluxes (GMF) for patients with Type 2 Diabetes Mellitus (T2DM). GMF twins utilized basic clinical physiological biomarkers as inputs of CKD. employed four diverse multi-ethnic cohorts ( n = 7072): Singaporean cohort (EVAS, 289) North American (NHANES, 1044) baseline identification, two multi-center (CDMD, 2119 SDR, 3627) 3-year risk stratification. subsequently conducted comprehensive study utilizing single dataset to evaluate the utility prediction. The GMF-based performed strongly, achieving an AUC between 0.80 0.82. In prediction, generated complete parameters attained high performance 0.86, while incomplete parameters, it achieved 0.75. is standard implementation our algorithm: HealthVector Diabetes®. established robust tool capable predicting stratifying future within time horizon. report correlation input their ability differentiate health states medication status at baseline, capability quantify progression rates. This holistic methodology provides insights into patients’ rates based on profile differences, enabling personalized care plans.

Language: Английский

---